Oral semaglutide cuts major heart risks in people with type 2 diabetes by 14%, offering a powerful pill-based option. Both ...

"Semaglutide is the first drug to reduce cardiovascular and kidney outcomes, improve walking capacity in a clinically meaningful way, and show benefits in symptoms and related quality of life in ...

(Reuters) -(To receive the full newsletter in your inbox for free sign up here) Novo Nordisk’s diabetes medicine Rybelsus, an oral form of the GLP-1 drug semaglutide, provides similar cardiovascular ...

New data suggests that the benefits of Novo Nordisk’s GLP-1 agonist semaglutide in preventing cardiovascular diseases may not simply be a result of weight loss. The analysis comes from long-term ...

25). The trial is the first to test the cardiovascular benefits of an oral GLP-1 inhibitor. Both injectable and oral forms of semaglutide are already approved by the U.S. Food and Drug ...

With Semaglutide, postmenopausal women can achieve significant weight loss, improve insulin sensitivity, and lower the risk ...

Semaglutide's benefits were consistent across subgroups, and it can be safely used with sodium-glucose co-transporter 2 inhibitors. Researchers suggest the 20% reduction in nonfatal heart attacks ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Recent study shows oral semaglutide reduces cardiovascular risk in type 2 diabetes patients, enhancing diabetes and heart ...

Researchers warned that to achieve such reductions, greater uptake of the medication among indicated patients is needed.

an oral form of the GLP-1 drug semaglutide, provides similar cardiovascular benefits as the injectable forms of the drug, researchers reported at the American College of Cardiology scientific ...